Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXO and Bevacizumab for Unresectable Liver-only Metastatic Colorectal Cancer
NCT01293942Phase 2Withdrawn
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2011
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Conversion to resectability during downsizing therapy. Planned start Mar 2011; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01293942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01293942.